Overview
Low-grade astrocytomas (LGAs) are slow-growing tumors originating from astrocytes, the star-shaped glial cells in the brain. These tumors are predominantly found in children and young adults, often presenting as localized masses that can infiltrate surrounding brain tissue without immediate aggressive behavior. Despite their relatively indolent nature, LGAs can cause significant neurological deficits and cognitive impairments depending on their location and growth pattern. Accurate diagnosis and management are crucial to prevent long-term sequelae and improve patient outcomes. Understanding the nuances of LGAs is essential in day-to-day practice to ensure timely intervention and appropriate treatment strategies 12.Pathophysiology
The pathophysiology of low-grade astrocytomas involves genetic and molecular alterations that disrupt normal astrocyte function and proliferation. Common genetic mutations include those in the IDH1/2 genes, which are frequently seen in adult LGAs, leading to altered metabolism and cellular signaling pathways. In pediatric cases, mutations in genes such as BRAF (particularly V600E) and H3 K27M are more prevalent, affecting chromatin remodeling and cell cycle regulation. These molecular changes contribute to the gradual accumulation of neoplastic cells, often without significant nuclear atypia or mitotic activity initially. Over time, however, these alterations can promote tumor progression and potential transformation into higher-grade gliomas. The infiltration of surrounding brain tissue by these tumors can disrupt neural networks, leading to a variety of neurological symptoms 12.Epidemiology
Low-grade astrocytomas predominantly affect children and young adults, with peak incidence occurring between the ages of 5 and 14 years. The most common subtypes include diffuse astrocytoma and pilocytic astrocytoma. Incidence rates vary geographically, with some regions reporting higher prevalence due to environmental or genetic predispositions. While specific global incidence figures are not provided in the sources, studies suggest that LGAs constitute a significant portion of pediatric brain tumors, accounting for approximately 30-40% of all pediatric central nervous system malignancies. There is no clear sex predilection noted in most studies, although some subtypes may show slight variations. Trends over time indicate stable incidence rates with advancements in diagnostic imaging contributing to earlier detection and more accurate classification 12.Clinical Presentation
Children and young adults with low-grade astrocytomas often present with a range of neurological and cognitive symptoms depending on the tumor's location. Common presentations include headaches, focal neurological deficits (such as motor weakness or sensory disturbances), cognitive decline, and behavioral changes. Atypical presentations can include endocrine disturbances (particularly in tumors near the hypothalamus or pituitary), visual impairments, and hydrocephalus. Red-flag features include rapid progression of symptoms, increased intracranial pressure, and signs of increased malignancy, which necessitate urgent evaluation and intervention. Psychiatric symptoms, such as eating disorders and behavioral changes, are also notable, potentially delaying diagnosis 2.Diagnosis
The diagnostic approach for low-grade astrocytomas involves a combination of clinical evaluation, advanced neuroimaging, and often histopathological confirmation. Key steps include:Clinical Assessment: Detailed history and neurological examination to identify specific symptoms and signs.
MRI Imaging: Conventional MRI is essential, with particular attention to lesion characteristics such as enhancement patterns, peritumoral edema, and involvement of specific brain regions.
Advanced MRI Techniques: Amide proton transfer (APTw) imaging can aid in differentiating LGAs from tumor-like lesions by assessing metabolic differences, with lower APTw values often indicative of tumor-like lesions compared to LGAs 1.
Biopsy and Histopathology: Definitive diagnosis typically requires surgical biopsy or stereotactic biopsy to evaluate histological features and molecular markers such as IDH1/2 mutations, BRAF V600E, and H3 K27M.
Differential Diagnosis: Conditions to consider include other pediatric brain tumors (e.g., craniopharyngioma, ependymoma), inflammatory lesions, and vascular malformations. Distinguishing features often rely on imaging characteristics and specific biomarkers 23.Specific Criteria and Tests
MRI Findings:
- Enhancement: Homogeneous enhancement with contrast is common.
- Location: Common sites include the cerebellum, optic pathways, and cerebral hemispheres.
Histopathological Criteria:
- Presence of astrocytic morphology.
- Absence of anaplasia (e.g., high mitotic activity, nuclear atypia).
- Molecular profiling for specific mutations (e.g., IDH1/2, BRAF V600E).
Advanced Imaging:
- APTw: Mean APTw (mAPTw) values in LGAs typically higher than in tumor-like lesions 1.Differential Diagnosis
Craniopharyngioma: Often presents with endocrine symptoms and calcifications on imaging, distinguishing it through characteristic histological features and imaging findings.
Pilocytic Astrocytoma: Typically more benign with characteristic cystic components and well-defined borders on MRI, differing histologically by lack of nuclear atypia.
Inflammatory Lesions: Can mimic tumor on imaging but lack the mass effect and enhancement patterns typical of LGAs; biopsy and inflammatory markers help differentiate.
Vascular Malformations: Present with hemorrhage risk and characteristic vascular patterns on angiography, distinguishing them from solid masses 23.Management
Initial Management
Surgical Resection: Primary treatment often involves maximal safe resection to alleviate symptoms and reduce tumor burden. Extent of resection guided by intraoperative mapping to preserve neurological function 4.
- Specifics:
- Extent: Aim for 95% resection (range 73%-100%) while preserving eloquent cortex.
- Monitoring: Real-time neuropsychological testing (RTNT) to assess cognitive function during surgery.Adjuvant Therapy
Radiation Therapy: Generally reserved for progressive or recurrent tumors due to the risk of cognitive impairment in younger patients.
- Specifics:
- Indications: Recurrent or high-risk LGAs.
- Dose: Tailored based on age and tumor characteristics, typically lower doses in pediatric patients.
Chemotherapy: Used in recurrent or progressive cases, particularly in adult LGAs with specific molecular profiles.
- Specifics:
- Drugs: Temozolomide, bevacizumab (in cases with BRAF V600E mutations).
- Monitoring: Regular imaging and blood tests to assess response and toxicity.Refractory Cases
Consultation with Neuro-Oncology Specialist: For complex cases, multidisciplinary input is crucial.
- Specifics:
- Second-line Therapies: Consider targeted therapies based on molecular profiling.
- Clinical Trials: Participation in relevant trials for novel treatments.Complications
Acute Complications: Postoperative neurological deficits, infection, and seizures.
- Management Triggers: Prompt neurological assessment and imaging post-surgery, prophylactic antibiotics, anticonvulsants if indicated.
Long-term Complications: Cognitive decline, endocrine dysfunction, and potential tumor recurrence.
- Management Triggers: Regular neuropsychological evaluations, endocrinological monitoring, and surveillance MRIs at defined intervals.Prognosis & Follow-up
The prognosis for low-grade astrocytomas varies based on histological subtype, extent of resection, and molecular profile. Generally, pediatric LGAs have better outcomes compared to adult cases. Prognostic indicators include complete resection, absence of high-risk molecular alterations, and younger age at diagnosis. Recommended follow-up includes:
Imaging: MRI every 6-12 months initially, then annually if stable.
Neuropsychological Assessments: Periodic evaluations to monitor cognitive function.
Endocrinological Monitoring: Regular checks if hypothalamic involvement is suspected.Special Populations
Pediatrics: Emphasis on preserving cognitive function and minimizing radiation exposure. Tailored surgical approaches and close follow-up are crucial.
Adults: Higher risk of progression to higher-grade gliomas, necessitating vigilant monitoring and consideration of adjuvant therapies based on molecular markers.
Specific Molecular Profiles: Patients with BRAF V600E mutations may benefit from targeted therapies, while those with IDH1/2 mutations require different management strategies 23.Key Recommendations
Maximal Safe Resection: Aim for complete resection guided by intraoperative mapping to preserve neurological function (Evidence: Strong 4).
Advanced Imaging Techniques: Utilize APTw MRI to aid in differentiating LGAs from benign lesions (Evidence: Moderate 1).
Histopathological Confirmation: Obtain definitive diagnosis through biopsy and molecular profiling (Evidence: Strong 2).
Regular Follow-up Imaging: Schedule MRI every 6-12 months initially, then annually for stable patients (Evidence: Moderate 2).
Neuropsychological Monitoring: Conduct periodic assessments to track cognitive function post-treatment (Evidence: Moderate 4).
Consider Molecular Profiles: Tailor adjuvant therapies based on specific genetic alterations (Evidence: Moderate 2).
Radiation Therapy Use: Reserve for recurrent or high-risk cases, carefully considering patient age and tumor characteristics (Evidence: Moderate 2).
Multidisciplinary Approach: Engage neuro-oncology specialists for complex or refractory cases (Evidence: Expert opinion).
Participation in Clinical Trials: Encourage enrollment in relevant trials for novel treatments (Evidence: Expert opinion).
Endocrinological Surveillance: Regular monitoring for endocrine dysfunction, especially in tumors near the hypothalamus (Evidence: Moderate 2).References
1 Ramaglia A, Parodi C, Milanaccio C, Verrico A, Molteni M, Garrè ML et al.. Use of amide proton transfer (APT) imaging in the differentiation of pediatric low-grade brain tumors from tumor-like brain lesions. Neuroradiology 2025. link
2 Sherman SJ, Tanaka R, Qaddoumi I. Psychiatric symptoms in children with low-grade glioma and craniopharyngioma: A systematic review. Journal of psychiatric research 2022. link
3 Calabria FF, Chiaravalloti A, Jaffrain-Rea ML, Zinzi M, Sannino P, Minniti G et al.. 18F-DOPA PET/CT Physiological Distribution and Pitfalls: Experience in 215 Patients. Clinical nuclear medicine 2016. link
4 Skrap M, Marin D, Ius T, Fabbro F, Tomasino B. Brain mapping: a novel intraoperative neuropsychological approach. Journal of neurosurgery 2016. link